NCT05824143View on ClinicalTrials.gov

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

July 7, 2023

Study Completion Date

July 7, 2023

Conditions
Healthy Participants
Interventions
DRUG

Darigabat

Oral tablet

DRUG

Carbamazepine

Oral tablets

Trial Locations (1)

32806

Orlando, Florida, Orlando

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05824143 - Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants | Biotech Hunter | Biotech Hunter